Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237049 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 644
- Enrollment target
NCT06237049 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 644 participants.
The verdict
NCT06237049, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 644 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.
Interventions
- BIOLOGICAL BNT162b2 (Omi XBB.1.5)
- BIOLOGICAL BNT162b2 (Omi XBB.1.5)/RIV
- BIOLOGICAL RIV
- OTHER Normal saline placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2024-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06237049
The ClinicalTrials.gov registry entry for NCT06237049 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 644 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BNT162b2 (Omi XBB.1.5) is the first listed.
NCT06237049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06237049 about?
NCT06237049 is a clinical study titled "A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults". The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this t...
What is the current status of trial NCT06237049?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 644 participants. The study started on 2024-01-31. Estimated completion is 2024-09-13.
What interventions are being tested in trial NCT06237049?
The interventions under investigation include: BNT162b2 (Omi XBB.1.5) (BIOLOGICAL), BNT162b2 (Omi XBB.1.5)/RIV (BIOLOGICAL), RIV (BIOLOGICAL), Normal saline placebo (OTHER).
Who is sponsoring clinical trial NCT06237049?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.